Published in Lancet Neurol on November 01, 2002
Pathways towards and away from Alzheimer's disease. Nature (2004) 8.72
AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One (2009) 1.23
Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol (2007) 1.19
Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci U S A (2005) 1.08
Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun (2009) 1.00
Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. Mol Neurodegener (2014) 0.99
Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice. Am J Pathol (2006) 0.94
Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics (2009) 0.86
Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis (2010) 0.84
Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. Drug Des Devel Ther (2009) 0.83
BACE1 inhibitory activity of fungal endophytic extracts from Malaysian medicinal plants. BMC Complement Altern Med (2011) 0.80
Present and prospective clinical therapeutic regimens for Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 0.79
Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? Open Neurol J (2009) 0.75
A bead-based cleavage method for large-scale identification of protease substrates. Sci Rep (2016) 0.75
YXQN Reduces Alzheimer's Disease-Like Pathology and Cognitive Decline in APPswePS1dE9 Transgenic Mice. Front Aging Neurosci (2017) 0.75
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain (2005) 2.27
Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest (2007) 2.19
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A (2004) 2.00
Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci (2002) 1.94
Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol (2008) 1.65
Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation (2005) 1.45
Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem (2004) 1.40
A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr Metab (Lond) (2005) 1.29
Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis. Mol Cell Biol (2012) 1.28
AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One (2009) 1.23
Capacitive calcium entry is directly attenuated by mutant presenilin-1, independent of the expression of the amyloid precursor protein. J Biol Chem (2002) 1.20
Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein. Mol Cell Biol (2012) 1.18
Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. Biochim Biophys Acta (2008) 1.15
Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β'-site increases Aβ generation. EMBO Mol Med (2011) 1.11
Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J (2002) 1.11
Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci U S A (2011) 1.09
GSK3 and Alzheimer's Disease: Facts and Fiction…. Front Mol Neurosci (2011) 1.09
Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei. J Neurosci (2010) 1.08
GSK-3α/β kinases and amyloid production in vivo. Nature (2011) 1.05
Unhampered prion neuroinvasion despite impaired fast axonal transport in transgenic mice overexpressing four-repeat tau. J Neurosci (2002) 1.04
Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration. Am J Pathol (2011) 1.04
Protein folding diseases and neurodegeneration: lessons learned from yeast. Biochim Biophys Acta (2008) 1.03
Alzheimer's disease: old problem, new views from transgenic and viral models. Biochim Biophys Acta (2010) 1.02
Mice lacking Dfna5 show a diverging number of cochlear fourth row outer hair cells. Neurobiol Dis (2005) 1.01
Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One (2013) 1.00
Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast. FEBS J (2005) 1.00
Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model. Int J Alzheimers Dis (2010) 0.98
Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med (2002) 0.96
Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast. Biochemistry (2005) 0.95
Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration. Am J Pathol (2008) 0.95
Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice. J Neurosci (2011) 0.95
Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine (2003) 0.95
Tau-4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice. FASEB J (2007) 0.94
Microtubule binding and clustering of human Tau-4R and Tau-P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3beta or cdk5. J Biol Chem (2006) 0.94
Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice. Am J Pathol (2006) 0.94
Occurrence and co-localization of amyloid beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice. Neurobiol Aging (2006) 0.92
Astrocytic calcium/zinc binding protein S100A6 over expression in Alzheimer's disease and in PS1/APP transgenic mice models. Biochim Biophys Acta (2004) 0.92
beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am J Pathol (2004) 0.92
Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain (2013) 0.91
beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. FEBS J (2010) 0.89
Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: a multi-electrode array study. Neurobiol Dis (2011) 0.89
Microglial upregulation of progranulin as a marker of motor neuron degeneration. J Neuropathol Exp Neurol (2010) 0.89
Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis (2012) 0.88
Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease. Respir Physiol Neurobiol (2011) 0.88
Role of alpha(2)-macroglobulin in fever and cytokine responses induced by lipopolysaccharide in mice. Am J Physiol Regul Integr Comp Physiol (2002) 0.88
Capacitative calcium entry induces hippocampal long term potentiation in the absence of presenilin-1. J Biol Chem (2003) 0.87
Mice lacking alpha(2)-macroglobulin show an increased host defense against Gram-negative bacterial sepsis, but are more susceptible to endotoxic shock. Eur Cytokine Netw (2002) 0.86
Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α. J Med Chem (2012) 0.86
Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neurosci Lett (2008) 0.86
Influence of exonic polymorphisms in the gene for LDL receptor-related protein (LRP) on risk of coronary artery disease. Atherosclerosis (2003) 0.86
Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol Aging (2008) 0.85
Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis (2010) 0.84
Age-related impairment of ultrasonic vocalization in Tau.P301L mice: possible implication for progressive language disorders. PLoS One (2011) 0.84
Isoflurane anesthesia precipitates tauopathy and upper airways dysfunction in pre-symptomatic Tau.P301L mice: possible implication for neurodegenerative diseases. Neurobiol Dis (2012) 0.83
Role of presenilin 1 in structural plasticity of cortical dendritic spines in vivo. J Neurochem (2011) 0.82
Mutant presenilin 1 alters synaptic transmission in cultured hippocampal neurons. J Biol Chem (2006) 0.82
Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase. Mol Brain (2013) 0.82
Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease. J Neural Transm (Vienna) (2011) 0.81
Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view. Proteomics (2002) 0.80
Characterization of a murine alpha 2 macroglobulin gene expressed in reproductive and cardiovascular tissue. Biol Reprod (2004) 0.80
Decreased expression of multidrug efflux transporters in the brains of GSK-3beta transgenic mice. Brain Res (2009) 0.80
Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast. FEMS Yeast Res (2010) 0.79
Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease. Mol Neurodegener (2014) 0.79
Preparation of cyclo-phen-type ligands: chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases. Chembiochem (2005) 0.79
Tauopathy differentially affects cell adhesion molecules in mouse brain: early down-regulation of nectin-3 in stratum lacunosum moleculare. PLoS One (2013) 0.77
Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci (2005) 0.77
Terminal hypothermic Tau.P301L mice have increased Tau phosphorylation independently of glycogen synthase kinase 3α/β. Eur J Neurosci (2014) 0.77
Glycogen synthase kinase-3β (GSK3β) expression in a mouse model of Alzheimer's disease: a light and electron microscopy study. Synapse (2013) 0.76
Glycogen synthase kinase-3beta affects size of dentate gyrus and species-typical behavioral tasks in transgenic and knockout mice. Behav Brain Res (2013) 0.76
Neuropathobiology in transgenic mice. The case of Alzheimer's disease. Methods Mol Biol (2003) 0.75
Translocation of the HMGI-C ( HMGA2) gene in a benign mesenchymoma (chondrolipoangioma). Virchows Arch (2001) 0.75